Moderna and Merck - mRNA based cancer vaccine
Phase 3 trial success triggered a $60 billion combined market cap surge, but regulatory approvals are yet to come.
The catalyst
On August 19, 2026, according to CNBC, Moderna and Merck announced that their combo treatment, the Phase 3 INTERPATH-001 trial of intismeran autogene (Moderna's personalised mRNA cancer vaccine) paired with Merck's Keytruda immunotherapy, met all main goals by preventing high-risk melanoma from returning or spreading to other organs and met a key secondary endpoint of preventing distant metastasis.
The news sent the share price of Moderna up as much as 180%. The price surge increased the market cap by $30 billion. Same happened in the case of Merck, which surged and increased its market cap by nearly $30 billion. In total, the surge added $60 billionto both companies' combined market cap.
Revenue and valuation context
Moderna's revenue declined from $3.2bn to $1.9bn in FY2025. According to analysts' estimates, melanoma sales alone could reach $3bn by 2035. For Merck, which already generates $65bn in annual revenue and has Keytruda as a proven blockbuster, the mRNA cancer vaccine is a meaningful but incremental addition to an already large and diversified portfolio.
In order to justify the recent surge at all, the trials below need to succeed across multiple cancer types and then achieve $10-13 billion in combined annual sales. Melanoma alone at $3bn would only justify a fraction of that.
The short squeeze
One of the main reasons for the surge was a short squeeze. Short interest in Moderna stood at 12.47% of the free float, marking it as one of the most shorted large-cap stocks. Positive trial data triggered a classic short squeeze. Trading volume was more than 15x the 50-day average. The scale of the percentage surge is different due to the size of each company. Merck's volume didn't trigger that much of a surge since it was not a target for short sellers.
Moderna (MRNA) daily chart - the gap and subsequent price surge. Source: LSEG
Is the surge realistic?
The market is pricing the best-case scenario, at a time when regulatory approvals have yet to be taken. Therefore, the surge in both companies is not realistic (as of now) and is bound to correct in the coming months, unless all the trial results are successful.
Pipeline and financials snapshot
Pipeline indications, market metrics (21 Aug 2026), and revenue concentration. Source: LSEG, Barclays estimates
Source note
CNBC was referenced for the INTERPATH-001 trial results announcement. Market data from LSEG as of 21 August 2026. Melanoma peak sales estimate from Barclays.
Author: Strategyland Research Team